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Abstract: We have modified a highperformance liquid chromatography (HPLC)
procedure for homocysteine assay using 7fluoro-2, 1, 3-benzoxadiazole-4-sulfonamide
(ABD-F) pre-column derivatization. In this
study, the thiol compounds were liberated
from plasma proteins by reduction with 2mercaptoethanol (BME) and derivatized with
a thiol-specific fluoregenic marker, ABD-F.
The derivatives were separated by reversedphase HPLC on a Hypersil C 18 column (4.6 x
150 mm; 5 µ) using isocratic elution with 0.1
M phosphate buffer pH 6.0 containing 8%
methanol and fluorescence detection.
Excitation and emission wavelengths were
386 and 516 nm. The peak of homocysteine
was eluted at 413 ± 25 s. Mean within-day
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Introduction
Homocysteine (Hcy) is a sulfur-containing aminoacid.
Circulating forms of Hcy include homocysteine itself, also
called the reduced form (1%), the oxidized form of Hcy
(5-10%), homocysteine-cysteine mixed disulfide (5-10%)
and protein-bound homocysteine (80-90%) (1). Total
Hcy is defined as the sum of all homocysteine species in
plasma, including free and protein-bound forms.
The determination of Hcy in plasma is useful both in
the diagnosis and follow-up of folate and cobalamine
deficencies and the rare inborn errors causing
homocystinuria
(2,
3).
In
addition,
hyperhomocysteinemia is an independent risk factor for
premature cardiovascular diasease (4). Thus, the accurate
determination of plasma concentrations of Hcy is
essential for understanding the role of Hcy in the
pathogenesis of related diseases.
The increasing interest in measuring total Hcy in
plasma has led to the development of several methods of
quantitation (5-7). A widely used technique is reversedphase high-performance liquid chromatography (HPLC)
with fluorescence detection (FD) (5, 8-13). The

and between-day precisions were determined
to be 1.96 and 4.34% CV, respectively. The
method was linear up to 100 µmol/L and
proved to be sensitive with a detection limit of
1 µmol/L for homocysteine.
In plasma samples from healthy adult
subjects, the concentration of homocysteine
was found to be higher in men than in women
(11.69 ± 2.9 versus 9.45 ± 1.78 µmol/L, p
= 0.002). The method is simple, sensitive,
and reproducible and allows a rapid
determination of total homocysteine in human
plasma under routine conditions.
Key Words: Homocysteine,
High
performance liquid chromatography, ABD-F,
Sulfamoylbenzofurazan, Mercaptoethanol

determination of total Hcy in plasma requires the
reduction of the disulfide bond between Hcy and other
thiols or albumin. The selection of reductant depends on
the separation and detection system used. Sulfhydrylcontaining reducing agents such as dithioerythritol,
dithioreitol, and mercaptoethanol liberate Hcy from
various disulfides (10). Sodium or potassium borohydride
(11) and tri-n-butylphosphine (8, 12) have also been
utilized as the reducing agent.
Hcy formed during the reduction step can be
reoxidized before derivatization or detection. Thiol
oxidation is inhibited by adding EDTA to the reaction
mixture. Precolumn derivatization with fluorogenic
reagents for thiols followed by HPLC has become
increasingly popular (5). Commonly used fluorogenic
reagents include monobromobimane (mBrB) (11),
ammonium
7-fluorobenzo-2-oxa-1,
3-diazole-4sulfonate (SBD-F) (9) and 7-fluoro-2, 1, 3benzoxadiazole-4-sulfonamide (ABD-F) (8). SBD-F and
ABD-F are halogenated sulfamoylbenzofurazans that have
been used to determine thiols, including Hcy (14). ABD-F
reacts quantitatively with thiols, including Hcy, at 50 °C
at pH 8.0–9.5 for 5–10 min (15).
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In this study, we describe a simple method for the
rapid determination of total plasma Hcy by using the
simultaneous mercaptoethanol reduction of disulfide
bonds and derivatization of sulfhydryl groups with ABDF reagent followed by HPLC-FD. Besides describing the
method, we also report on its use to determine
differences between the concentrations of total Hcy in the
plasma of healthy adults and patients.

Materials and Methods
Reagents
DL-Homocysteine, L-cysteine (Cys), cysteinylglycine
(CysGly), glutathione (GSH), and 7-fluoro-2, 1, 3-benzoxadiazole-4-sulfonamide (ABD-F) were obtained from
Sigma (St. Louis, MO, U.S.A.). 2-Mercaptoethanol (BME),
sodium tetraborate, EDTA disodium salt, trichloroacetic
acid (TCA), HPLC-grade methanol, Na2HPO4 and
KH2PO4 were from Merck (Darmstadt, Germany).
HPLC-grade water was produced by a Milli-Q water
purification system from Millipore (Elga, Germany).
Standard Solutions
DL-Homocysteine (0.5 mmol/L), cysteinylglycine (0.5
mmol/L), glutathione (1 mmol/L) and L-cysteine (2
mmol/L) were dissolved in 0.1 mol/L HCl. These stock
solutions were further diluted in borate buffer (0.05
mmol/L, pH 8.0, containing 2 mmol/L Na2EDTA) to
known concentrations.
Instrumentation
Separation and quantification were performed with a
Hewlett Packard 1050 HPLC-FD equipped with a
Phenomenex (CA, U.S.A.) Hypersil C 18 reverse-phase
analytical column (4.6 x 150 mm, 5 µm particles)
protected by a Phenomenex (CA, U.S.A.) Hypersil C 18
guard column (4.6 x 50 mm, 5 µm particles).
Fluorescence intensities were measured with excitation at
386 nm and emission at 516 nm. Peaks were quantified
by reference to a calibration curve constructed by
triplicate analysis of Hcy standards (0, 2.5, 5, 10, 15, 25,
50 and 100 µmol/L) and plotting peak height versus Hcy
concentration. The linear regression equation obtained
from the calibration curve was used to calculate the
concentration of Hcy in unknown plasma samples from
healthy donors and patients. Calibration curves for Cys,
CysGly and GSH were also established similarly.
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Sample Collection and Subjects
Plasma was used to determine total Hcy and other
thiols. Blood was obtained by venipuncture and collected
into evacuated tubes containing EDTA. The tubes were
placed on ice and the blood cells were removed without
delay by centrifugation for 10 min at 2000 x g (11).
Plasma was stored at –40 °C until analysis. Control blood
samples were collected from fasting, apparently healthy
adult volunteers (25 men and 21 women, aged 25–47
years). We also studied 10 male patients with premature
cardiovascular disease diagnosed by coronary
angiography, 11 male patients with hypogonadism and
six patients with Behçet’s disease. Two of the
hypogonadic patients were receiving testosterone
replacement therapy.
Method
One hundred microliters of plasma or standards was
mixed with 20 µL of 0.03 mol/L borate buffer, pH 8.0,
containing 4 mmol/L Na2EDTA. Ten microliters of 2mercaptoethanol (0.1 mol/L dissolved in 0.05 mol/L
sodium tetraborate) was added. The mixture was
incubated at room temperature for 30 min to accomplish
the reduction of Hcy and the mixed disulfide (cysteinehomocysteine) as well as the release of protein-bound
homocysteine and other plasma thiols. This method
therefore measures total (free plus protein-bound)
plasma Hcy levels. After reduction, 50 µL of ABD-F
reagent (23 mmol/L dissolved in 0.05 mol/L borate
buffer, pH 8.0, containing 4 mmol/L Na2EDTA) was
added. The mixture was incubated for 10 min at 50 °C to
accomplish the complete derivatization of Hcy and other
plasma thiols. Deproteinization was achieved by the
addition of 20% (w/v) TCA (40 µL) at 2 °C and
centrifugation at 23 000 g. for 10 min at 2 °C. The clear
supernatant (150 µL) was stored at 4 °C for HPLC
analysis on the same day.
All samples were analyzed on a Hewlett Packard 1050
HPLC-FD system. The mobile phase was 0.1 mol/L
phosphate buffer, pH 6.0, containing 8% (v/v) methanol.
HPLC was performed under isocratic conditions at a flow
rate of 1.6 mL/min. Twenty microliters of sample were
used for each injection. The column effluent was
monitored by a fluorescence detector for 14 min.
Excitation and emission wavelengths were at 386 and
516 nm, respectively.
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To investigate the recovery and precision of the assay,
Hcy was added to the plasma pool so as to increase its
concentration by 5 and 10 µmol/L (S5 and S10). These
samples were stored at –40 °C until analysis. The
concentrations in the plasma pool (P) and in the plasma
pools with added standards (PS5 and PS10) were then
determined in 10 replicates and analytical recovery was
calculated as follows:
Recovery (%) = 100 . (PS – P) / S
Statistical Analysis
The statistical analyses were performed by using SPSS
version 9.0 for Windows. All results were expressed as
means ± standard deviation (SD). Mann-Whitney U and
Kruskal-Wallis nonparametric tests were used to assess
overall differences between the healthy (control) group
and the different groups of and patients, with p < 0.05
being considered statistically significant.

Results
As shown in Figure 1, the four thiols were
separated with near-baseline resolution using the
standard solutions. The retention times of Cys, Hcy,
CysGly and GSH were 299 ± 20, 413 ± 25, 530 ± 20
and 600 ± 30 s, respectively. The retention times were
also identical in the HPLC chromatograms of healthy
subjects (Figure 2) and patients (Figure 3) using
plasma samples.
Determination of total Hcy in plasma requires the
reduction of the disulfide bond between Hcy and other
thiols before the derivatization step. After testing with
different concentrations of BME as a reducing agent, we
decided to use 0.1 mol/L BME for the optimum reduction
of the thiols. BME was found to be effective for reduction
of the thiols over pH 7.0 and was compatible with ABDF reagent in this pH range.

1STOS-00-TD

11.0

Figure 1.

HPLC chromatogram of 100
µmol/L cysteine and 5 µmol/L
homocysteine, cysteinylglycine,
and glutathione standards. Peaks:
1 = Cys, 2 = Hcy, 3 = CysGly, 4 =
GSH.

Figure 2.

HPLC chromatogram of the thiols
in total plasma from a healthy
subject. Peaks: 1 = Cys, 2 = Hcy,
3 = CysGly, 4 = GSH.
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Figure 3.
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HPLC chromatogram of the thiols
in total plasma from a patient with
premature cardiovascular disease.
Peaks: 1 = Cys, 2 = Hcy, 3 =
CysGly, 4 = GSH.
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Calibration curves were obtained by assaying known
concentrations of standards. The standard curve for Hcy
was linear over a concentration range of 0–100 µmol/L;
higher concentrations were not tested as they were not
encountered in normal populations. Linear regression
analysis of the results gave y = 0.0285 + 0.3027 x (r =
0.9998). The curves for Cys, CysGly and GSH were also
linear: y = -1.9012 + 0.1304 x (r = 0.9958), y = 0.2058
+ 0.2238 x (r = 0.9947) and y = 0.8616 + 0.2028 x (r
= 0.9922) (data not shown). The detection limit of the
method for Hcy was 1 µmol/L.
Performance parameters for the determination of
plasma total Hcy levels, as calculated from the repeat
analysis of three plasma samples, are summarized in
Table 1. The mean recovery of Hcy added to a plasma
pool to final concentrations of 5.0 and 10.0 µmol/L was
97.4%. The within- and between-day coefficients of
variation (CV) for Hcy were <5%.
Total plasma Hcy was determined by the current
method in healthy subjects and patients (Table 2). The
mean (±SD) total plasma Hcy in 25 healthy men was
11.69 (±2.32); the corresponding value in healthy
women was 9.45 (±1.78) µmol/L. The difference
between the mean value for middle aged healthy males
and females was significant at p < 0.001.
The concentrations of total Hcy in plasma were
significantly higher in patients with premature
atherosclerotic vascular disease (p = 0.0026) and
Behçet’s disease (p = 0.035) than in healthy subjects. The
differences between patients with hypogonadism and
healthy subjects were not statistically significant (p =
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0.17), but the plasma concentrations of total Hcy in two
hypogonadic patients receiving hormonal replacement
therapy were found to be about two-fold higher than
those of healthy subjects.

Discussion
Hyperhomocysteinemia is a possible risk factor for
premature vascular disease, and is independent of other
factors such as hypertension, diabetes, smoking, and
plasma cholesterol. In coronary artery disease, the ratio
for mean plasma Hcy in patients vs. controls was 1.2 to
1.8 (1, 13, 16, 17). Thus, methods with high precision
and sensitivity are required to detect a minimal rise in
total Hcy concentrations. Here we describe a simple and
rapid method for the determination of total Hcy by using
HPLC-FD.
Of the various thiol-specific derivatization reagents (8,
9, 13-15, 18), we chose ABD-F as a suitable reagent
because mBrB gives rise to several reagent peaks that
may interfere with Hcy determination and SBD-F requires
more drastic conditions (pH 9.5, and 60 °C for 1 h). In
addition, the short reaction time of ABD-F helps to
prevent the reoxidation of Hcy. The derivatization of Hcy
and other thiols with the ABD-F reagent proceeds
optimally above pH 7.0 (14, 15). In our study, BME was
used together with ABD-F and was compatible with it in
this pH range. This eliminated the necessity of adjusting
pH for the mixture. As this pH range is also suitable for
plasma samples, the extensive dilution of plasma was
therefore prevented.
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Recovery

Within-day (n = 10)

Between-day (n = 10)

a

Sample

Added, µmol/L

Recovered, %

Mean ± SD (CV%)b

Mean ± SD (CV%)b

PS 10

10.0

98.9 ± 1.8

19.04 ± 0.36 (1.91)

18.81 ± 0.86 (4.58)

PS 5

5.0

95.9 ± 4.5

13.52 ± 0.27 (2.01)

13.62 ± 0.60 (4.42)

P

0.0

---

8.89 ± 0.17 (1.96)

8.74 ± 0.35 (4.04)

a
b

Table 1.

Precision and recovery of the
assay.

described in the text.
mean and standard deviation are expressed as µmol/L.

Table 2.

Comparison of plasma total Hcy levels in patients and healthy subjects.
Healthy subjects

Patients

Men

Women

Atherosclerosis

Hypogonadism

n

25

21

10

11

6

Age (mean)

35

33

40

26

30

11.69 ± 2.32*

9.45 ± 1.78

18.93 ± 9.0 **

13.20 ± 1.95

14.44 ± 3.72***

Hcy (mean ± SD)a

Behçet’s Disease

a

mean and standard deviation are expressed as µmol/L.
* p < 0.001, ** p < 0.005, *** p < 0.05.

We used 20% TCA for removing plasma proteins
after the reduction and derivatization steps. The time of
deproteinization (pre- versus post-derivatization) was
found not to affect the results of the Hcy assay. The
sample preparation procedure involved minimal dilution
(2.2-fold) of the plasma sample. This increased the
sensitivity of our method. We tested different mobile
phases to achieve the optimum elution of the thiols.
The mean ± SD within- and between-day CVs% for
Hcy were determined to be 1.96 ± 0.27 and 4.43 ± 0.6,
respectively. These values are similar to those obtained
with other widely used methods (1, 13). Significantly
higher concentrations of total Hcy were found in plasma
from men (p = 0.002). These findings are therefore
consistent with most other studies (11, 19). We also
found plasma Hcy levels to be 1.2- to 1.8-fold higher in
patients with premature cardiovascular disease as
compared to healthy subjects. This moderate increase in
plasma Hcy above normal is statistically associated with
premature cardiovascular disease (1). The plasma
concentrations of total Hcy in hypogonadic patients
tended to be elevated compared with those in healthy

subjects, but the difference was significant only in two
hypogonadic patients receiving hormonal replacement
therapy. Therefore, we believe that studies on patients
with hypogonadism will help to explain the relations
between sex hormones and plasma Hcy levels. There are
studies related to the high plasma Hcy levels in patients
with autoimmune disease (13, 20). We also found
significantly high plasma Hcy levels in patients with
Behçet’s disease.
In conclusion we have developed a HPLC method for
measuring total homocysteine in plasma, using ABD-F and
BME as a fluoregenic marker and reducing agent,
respectively. The method is simple, sensitive and suitable
for routine use in the clinical laboratory.
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